The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies
Open accessAbstract
BACKGROUND: Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. MATERIALS AND METHODS: Data from two randomized first-line panitumumab trials were analyzed for treatment outcomes by primary tumor sidedness for RAS WT patients. PRIME (phase 3; NCT00364013) compared panitumumab plus FOLFOX versus FOLFOX alone; PEAK (phase 2; NCT00819780) compared panitumumab plus FOLFOX versus bevacizumab plus FOLFOX. Primary tumors located in the cecum to transverse colon were coded as right-sided, while tumors located from the splenic flexure to rectum were considered left-sided. RESULTS: Tumor sidedness ascertainment (RAS WT population) was 83% (n = 559/675); 78% of patients (n = 435) had left-sided and 22% (n = 124) had right-sided tumors. Patients with right-sided tumors did worse for all efficacy parameters compared with patients with left-sided disease in the RAS WT population and also in the RAS/BRAF WT subgroup. In patients with left-sided tumors, panitumumab provided better outcomes than the comparator treatment, including on median overall survival (PRIME: 30.3 versus 23.6 months, adjusted hazard ratio = 0.73, P = 0.0112; PEAK: 43.4 versus 32.0 months, adjusted hazard ratio = 0.77, P = 0.3125). CONCLUSION: The results of these retrospective analyses confirm that in RAS WT patients, right-sided primary tumors are associated with worse prognosis than left-sided tumors, regardless of first-line treatment received. RAS WT patients with left-sided tumors derive greater benefit from panitumumab-containing treatment than chemotherapy alone or combined with bevacizumab, including an overall survival advantage (treatment difference: PRIME 6.7 months; PEAK 11.4 months). No final conclusions regarding optimal treatment could be drawn for RAS WT patients with right-sided mCRC due to the relatively low number of paxtients. Further research in this field is warranted. TRIAL REGISTRATION (CLINICALTRIALS.GOV): PRIME (NCT00364013), PEAK (NCT00819780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 2×
“Recently, RAS mutations (KRAS and NRAS exons 2/3/4) have been shown to be associated with lack of response to antiepidermal growth factor receptor (EGFR) therapy [5].”
BackgroundSelf-citationSartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016 · cited 1×
“HER2 amplification has been reported as a mechanism of resistance to anti-EGFR treatment and therapeutic approaches for patients with HER2positive mCRC tumors are in development [7].”
BackgroundSelf-citationTejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709 · cited 4×
“These analyses confirmed the prognostic effect of tumor sidedness in patients with RAS WT and RAS/BRAF WT mCRC, in line with data previously reported in the literature [12, 15, 17, 21, 22].”
ResultInfluentialSelf-citationPietrantonio, F., Petrelli, F., Coinu, A., Di Bartolomeo, M., Borgonovo, K., Maggi, C., Cabiddu, M., Iacovelli, R., Bossi, I., Lonati, V., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.01.054 · Cited by 486
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Early‐onset colorectal cancer in young individuals
Mauri, G., Sartore‐Bianchi, A., Russo, A., Marsoni, S., Bardelli, A., & Siena, S. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12417 · Cited by 634
Self-citationDifference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y. (2018) · Gastroenterology Research · doi:10.14740/gr1062w · Cited by 553
Dueland, S., Syversveen, T., Solheim, J. M., Solberg, S., Grut, H., Bjørnbeth, B. A., Hagness, M., & Line, P.-D. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003404 · Cited by 360
Primary and metastatic peritoneal surface malignancies
Cortés-Guiral, D., Hübner, M., Alyami, M., Bhatt, A., Ceelen, W., Glehen, O., Lordick, F., Ramsay, R., Sgarbura, O., Van Der Speeten, K., et al. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00326-6 · Cited by 308
Metadata
- Authors
- Boeckx, N., Koukakis, R., Op de Beeck, K., Rolfo, C., Van Camp, G., Siena, S., Tabernero, J., Douillard, J.-Y., André, T., & Peeters, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 28
- Issue
- 8
- Pages
- 1862-1868
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2609363527
- Cited by
- 217
- References
- 5
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.